I completed my PhD at the University of Manchester, examining several cytological conditions that occur when cells commit to apoptosis. In 2001, I obtained an 18 month Wellcome Showcase award for Innovative research where I explored the use of intrabodies tagged to fluorescent proteins to create an in-cyto immunoassay. The idea went by the acronym LADDERS (Live Antigen Detection Dual Epitope Reporter System). In 2003, I started working for AstraZeneca were I was employed in the Systems Biology group, Pathways.

I left AZ in October 2007 to set up Imagen Biotech with my colleague Gareth Griffiths. Our aim is for Imagen Biotech to serve large pharma, small biotech and academia providing a first class High Content Screening service. ()

Initially my career started out in academia and gave me many years postdoc experience. Subsequently I took a challenging role in industry in the field of Systems Biology. Working in this field led me to specialise in High Content Analysis which is highly compatible with generating the very rich data sets required for Systems Biology. Promotion to a position central to the High Content Screening facility within AstraZeneca, provided me with a deep understanding of its usage and benefits across a large number of diverse projects. I gained hands on experience in a whole array of algorithms for analysing images and now have advanced expert knowledge in this area. My desire was to form my own company based around these skills and I left to become Science Director and co-founder of Imagen Biotech. ()

Jim Bristow brings his extensive corporate experience to the board. Jim has had senior positions in a variety of companies/industry sectors including Beecham Group Plc, Coloroll Home Furnishings, Orbis plc and the and has been involved with the biotech sector for the last 10 years. He most recently established the MedTECH Centre, an NHS health-technology incubator based in Manchester. Jim has a strong background in sales and management. He has also successfully raised over £15 million from the market and has led an institutionally funded management buy out. He is also a non-exec director on the board of Oncoprobe Ltd.